181 related articles for article (PubMed ID: 1890139)
21. Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
Gust R; Bernhardt G; Spruss T; Krauser R; Koch M; Schönenberger H; Bauer KH; Schertl S; Lu Z
Arch Pharm (Weinheim); 1995 Sep; 328(9):645-53. PubMed ID: 7487421
[TBL] [Abstract][Full Text] [Related]
22. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
[TBL] [Abstract][Full Text] [Related]
23. Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Spruss T; Bernhardt G; Schönenberger H; Engel J
J Cancer Res Clin Oncol; 1993; 119(3):142-9. PubMed ID: 8418086
[TBL] [Abstract][Full Text] [Related]
24. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
[TBL] [Abstract][Full Text] [Related]
25. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
[TBL] [Abstract][Full Text] [Related]
26. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285
[TBL] [Abstract][Full Text] [Related]
27. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
[TBL] [Abstract][Full Text] [Related]
28. DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II).
Lee HH; Palmer BD; Baguley BC; Chin M; McFadyen WD; Wickham G; Thorsbourne-Palmer D; Wakelin LP; Denny WA
J Med Chem; 1992 Aug; 35(16):2983-7. PubMed ID: 1501223
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands.
Coluccia M; Nassi A; Boccarelli A; Giordano D; Cardellicchio N; Locker D; Leng M; Sivo M; Intini FP; Natile G
J Inorg Biochem; 1999 Oct; 77(1-2):31-5. PubMed ID: 10626350
[TBL] [Abstract][Full Text] [Related]
32. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
Bernhardt G; Reile H; Birnböck H; Spruss T; Schönenberger H
J Cancer Res Clin Oncol; 1992; 118(1):35-43. PubMed ID: 1309532
[TBL] [Abstract][Full Text] [Related]
33. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Gust R
Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
[TBL] [Abstract][Full Text] [Related]
34. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
35. New synthetic route to [bis-1,2-(aminomethyl)benzene]dichloroplatinum(II) complexes, screening for cytotoxic activity in cisplatin-sensitive and resistant human cancer cell lines, and reaction with glutathione.
Rinke K; Grünert R; Bednarski PJ
Pharmazie; 2001 Oct; 56(10):763-9. PubMed ID: 11683118
[TBL] [Abstract][Full Text] [Related]
36. In Vitro Anticancer Evaluation of Platinum(II/IV) Complexes with Diisoamyl Ester of (S,S)-ethylenediamine-N,N'-di-2-propanoic Acid.
Zmejkovski BB; Pantelić N; Filipović L; Aranđelović S; Radulović S; Sabo TJ; Kaluđerović GN
Anticancer Agents Med Chem; 2017; 17(8):1136-1143. PubMed ID: 27928952
[TBL] [Abstract][Full Text] [Related]
37. [The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers].
Karl J; Schönenberger H
Arch Pharm (Weinheim); 1988 Jul; 321(7):405-10. PubMed ID: 3219056
[No Abstract] [Full Text] [Related]
38. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
[TBL] [Abstract][Full Text] [Related]
39. Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes.
Jennerwein M; Wappes B; Gust R; Schönenberger H; Engel J; Seeber S; Osieka R
J Cancer Res Clin Oncol; 1988; 114(4):347-58. PubMed ID: 3410875
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
